SK Biopharm's CTO On Diversity In Open Innovation
Primarily Looking At Oncology, CNS Collaborations
Executive Summary
SK Biopharm’s chief technology officer outlines how the company’s open innovation strategy may vary and what he sees as essential in new drug development.